This article is more than 5 years old. Information may no longer be current.

Avedro licenses iontophoresis patents from EyeGate

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyeGate Pharma’s iontophoresis patents in the field of corneal collagen cross-linking have been exclusively licensed to Avedro, according to a news release.

“This license allows Avedro the rights to pursue any use of EyeGate’s systems in the field of corneal collagen cross-linking,” David Muller, PhD, CEO of Avedro, said in the release.

Iontophoresis may be able to deliver riboflavin into the cornea without the need to remove the corneal epithelium, according to the release. Currently, removal of the epithelium is common when cross-linking is used to treat post-LASIK ectasia or degenerative keratoconus.

Removal results in patient discomfort for up to 24 hours. It also has a negative impact on vision for several days while the epithelium regrows.

“Iontophoresis is a delivery approach, among others, we intend to investigate to determine if it may offer any additional benefits to the excellent clinical results we have achieved with ParaCel, our current transepithelial cross-linking formulation,” Muller said in the release.